3–4 speakers each briefly defend a different approach in this open debate. The audience votes on the most promising strategy.

• Lipid chemistry vs formulation tuning vs hybrid systems
• Passive biodistribution control vs active targeting (ligands, peptides, etc.)
• Incremental optimisation vs completely new delivery paradigms
• What actually translates in vivo vs what only works in preclinical models